Secondary hyperparathyroidism (SHPT) refers to one of the serious, common, and progressive complication associated with Chronic Kidney Disease (CKD) that is mainly characterized by high levels of parathyroid hormone, mineral metabolism abnormalities, and parathyroid gland hyperplasia. Failing kidneys are unable to convert Vitamin A to its active form as they do not adequately excrete phosphate resulting into formation of insoluble calcium phosphate by the body thus, leading to secondary hyperparathyroidism. The common signs and symptoms of the disease includes bone and joint pain as well as limb deformities. The disturbances caused in the secondary hyperparathyroidism patients may lead to poor quality of life and short life expectancy.
Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/1570
Rising prevalence of benign prostate hyperplasia in adults is expected to drive the growth of Secondary Hyperparathyroidism Treatment Market: Market Dynamics
Rising incidence of chronic kidney diseases is one of the major factors responsible for growth of the global secondary hyperparathyroidism treatment market. According to Centers of Disease Control & Prevention (CDC) 2017, 30 million people or 15% of the U.S. adults are estimated to have chronic kidney disease, out of which 48% suffer severely with reduced kidney function, however, are not aware of having a CKD. Moreover, according to the National Kidney Foundation 2016, 10% of the population across the world are affected with chronic kidney diseases. Additionally, extensive research in the field of nephrology to come up with new drugs and therapies for treatment of secondary hyperparathyroidism is responsible for fueling growth of the market. For instance, Sanofi SA’s Hectorol capsules is undergoing Phase 3 clinical trials to evaluate the safety and efficacy of this medication in reducing the level of secondary hyperparathyroidism in pediatric patients with chronic kidney diseases at stage 3 and 4. The drug is expected to complete its study in December 2017, and be commercially available in market. However, side effects usually associated with secondary hyperparathyroidism treatment such as muscle spasm, diarrhea, and vomiting may cause hindrance to growth of the market.
Ask for TOC : https://www.coherentmarketinsights.com/ongoing-insight/toc/1570
Secondary Hyperparathyroidism Treatment Market: Competitive Analysis
Key players operating in the global secondary hyperparathyroidism treatment market include AbbVie, Inc., Shire, Inc., OPKO Health, Amgen, Inc., Sanofi SA, F. Hoffmann-La Roche AG, Kyowa Hakko Kirin Co. Ltd., KAI Pharmaceuticals, Astellas Pharma, Inc., Deltanoid Pharmaceuticals, and Leo Pharma. Major players are focusing on innovation and new product development, to maintain their position in the market and enhance their share. For instance, in June 2016, OPKO Health introduced Rayaldee (calcifediol) for the treatment of SHPT in adults with stage 3 or 4 of chronic kidney disease.
Secondary Hyperparathyroidism Treatment Market: Market Taxonomy
The global secondary hyperparathyroidism treatment market by Coherent Market Insights is segmented on the basis of drug class and distribution channel.
On the basis of drug class, the global secondary hyperparathyroidism treatment market is segmented into:
- Vitamin D Derivatives
- Phosphate Binders
- Calcium-Based Binders
- Non-Calcium Based Binders
On the basis of distribution channel, the global secondary hyperparathyroidism treatment market is segmented into:
- Hospital Pharmacies
- Retail Pharmacies
Request for Discount Before Buying This Business Reports @ https://www.coherentmarketinsights.com/insight/request-discount/1570
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154